Gujarat Kidney and Super Speciality Ltd

Gujarat Kidney and Super Speciality Ltd has announced that its Board of Directors will convene on November 4, 2026. The primary agenda item is the consideration and approval of the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026. In line with SEBI regulations, the trading window for designated persons and their immediate relatives has been closed from October 1st, 2026, and will reopen 48 hours after the announcement of these financial results.

Gujarat Kidney and Super Speciality Ltd has announced the closure of its trading window from October 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will reopen 48 hours after the declaration of the un-audited financial results for the quarter ending September 30, 2026, by the Board of Directors. The date of the board meeting to consider these results will be communicated separately.

Gujarat Kidney and Super Speciality Ltd issued a corrigendum to its Annual Report for FY 2025-26, originally submitted on September 03, 2026. The company identified inadvertent omissions in the PDF version, specifically regarding qualifications in the Secretarial Audit Report and the management's response, which were part of the final approved report. The corrigendum clarifies these disclosures. The company emphasized that these corrections do not affect the standalone or consolidated financial statements, statutory auditors' report, financial position, financial performance, the 7th Annual General Meeting notice, proposed resolutions, or members' voting rights. The updated Annual Report, incorporating these changes, has been made available on the company's website.

Gujarat Kidney and Super Speciality Ltd has announced its 7th Annual General Meeting (AGM) will be held on Monday, September 28, 2026, at 9:30 a.m. in physical mode. The AGM will cover ordinary business, including the adoption of audited standalone and consolidated financial statements for the financial year 2025-26, and the appointment of a director retiring by rotation. Special business includes the appointment of M/s SPANJ & Associates as Secretarial Auditors for five years and Mr. Paresh Dhoti as an Independent Director for five years. Mrs. Disha Bharpoda is also proposed for appointment as an Independent Director.

Gujarat Kidney and Super Speciality Ltd has submitted a revised annual report for FY 2025-26, including the notice for its 7th Annual General Meeting (AGM) scheduled for September 28, 2026. The revision was necessary to incorporate the Secretarial Audit Reports for material subsidiaries, which were inadvertently omitted from the initial submission. The AGM will cover the adoption of audited standalone and consolidated financial statements, the appointment of a director retiring by rotation, the appointment of M/s SPANJ & Associates as Secretarial Auditors for five years, and the appointment of Mr. Paresh Dhoti as an Independent Director.

Gujarat Kidney & Superspeciality Limited has announced its 7th Annual General Meeting (AGM) to be held on September 28, 2026. The meeting will cover the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026. Key agenda items include the re-appointment of a director retiring by rotation and the appointment of M/s SPANJ & Associates as Secretarial Auditors for a five-year term. Additionally, the appointment of Mr. Paresh Dhoti as an Independent Director will be considered.

Gujarat Kidney And Superspeciality Ltd has issued a pre-advertisement for its 7th Annual General Meeting (AGM). The meeting is scheduled to be held on Monday, September 28, 2026, at 9:30 IST in a physical mode. The company has complied with SEBI Listing Regulations and MCA circulars by publishing notices in the Financial Express (Ahmedabad Edition) and Gujarat Mitra (Gujarati Edition) on September 1, 2026. Further details will be available on the company's website, www.gujaratsuperspecialityhospital.com.

Gujarat Kidney and Super Speciality Ltd announced the appointment of Mrs. (Dr) Disha Bharpoda as an Additional Non-Executive Independent Director. The appointment is effective from August 24, 2026, and is subject to shareholder approval at the upcoming Annual General Meeting. Mrs. Bharpoda holds an MD in Radiology and has prior experience as a Senior Resident Doctor and running her own radiology center. The board also noted shareholder approval via postal ballot for a variation in the objects/terms of utilization of IPO proceeds. The meeting was held on August 24, 2026.

Gujarat Kidney and Super Speciality Ltd announced the appointment of Mrs. (Dr) Disha Bharpoda as an Additional Non-Executive Independent Director. The appointment, effective August 24, 2026, is subject to confirmation by shareholders at the ensuing Annual General Meeting. Mrs. Bharpoda holds an MD in Radiology and has experience as a Senior Resident Doctor and runs her own radiology center. She is not related to any existing director of the company. The board also noted shareholder approval for a variation in IPO proceeds utilization.

Gujarat Kidney and Super Speciality Limited has submitted its Third Monitoring Agency Report for the quarter ended June 30, 2026. The report, prepared by Brickwork Ratings India Private Limited, details the utilization of funds raised through the company's Initial Public Offer (IPO). The total funds raised amounted to ₹250.80 Crore. The report indicates no deviation from the stated objects for the utilization of these funds. This information is also available on the company's website.